Progresses in research and development of antibody-drug conjugate
Wu Gang,
Fu Zhihao,
Xu Gangling,
Wang Wenbo,
Yu Chuanfei,
Wang Lan,
Wang Junzhi
Affiliations
Wu Gang
Key Laboratory of the Ministry of Health for Research on Control and Standardization of Biotech Products, National Institutes for Food and Drug Quality, Beijing 102629, China
Fu Zhihao
Key Laboratory of the Ministry of Health for Research on Control and Standardization of Biotech Products, National Institutes for Food and Drug Quality, Beijing 102629, China
Xu Gangling
Key Laboratory of the Ministry of Health for Research on Control and Standardization of Biotech Products, National Institutes for Food and Drug Quality, Beijing 102629, China
Wang Wenbo
Key Laboratory of the Ministry of Health for Research on Control and Standardization of Biotech Products, National Institutes for Food and Drug Quality, Beijing 102629, China
Yu Chuanfei
Key Laboratory of the Ministry of Health for Research on Control and Standardization of Biotech Products, National Institutes for Food and Drug Quality, Beijing 102629, China
Wang Lan
Key Laboratory of the Ministry of Health for Research on Control and Standardization of Biotech Products, National Institutes for Food and Drug Quality, Beijing 102629, China
Wang Junzhi
Key Laboratory of the Ministry of Health for Research on Control and Standardization of Biotech Products, National Institutes for Food and Drug Quality, Beijing 102629, China
Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized. Twelve ADCs have been approved worldwide, since the therapeutic ADC was marketed for the first time in 2000. There are two imported and one domestic ADCs approved to date in China. In this paper, the development of ADCs in recent years was summarized, and the key elements of ADCs such as antigenic site, linker, payload and conjugation mode were reviewed in order to provide comprehensive information of ADCs and promote their research and development in the future.
